Literature DB >> 31759370

An Investigation on the Therapeutic Potential of Butein, A Tretrahydroxychalcone Against Human Oral Squamous Cell Carcinoma.

Devivasha Bordoloi1, Javadi Monisha1, Nand Kishor Roy1, Ganesan Padmavathi1, Kishore Banik1, Choudhary Harsha1, Hong Wang2,3, Alan Prem Kumar2, Frank Arfuso4, Ajaikumar B Kunnumakkara5.   

Abstract

BACKGROUND: Oral squamous cell carcinoma (OSCC) is one of the most predominant cancers in India. With advances in the field of oncology, a number of therapies have emerged; however, they are minimally effective. Consequently, there is a need to develop safe and effective regimens for the treatment of OSCC. Butein, a tetrahydroxychalcone has been found to exhibit potent antioxidant, anti-inflammatory, and also anti-tumor effects against several cancer types. However, its effect on OSCC is not studied yet.
METHODS: The effect of butein on the viability, apoptosis, migration and invasion of OSCC cells was evaluated using MTT, colony formation, PI/FACS, live and dead, scratch wound healing, and matrigel invasion assays. Further Western blot analysis was done to evaluate the expression of different proteins involved in the regulation of cancer hallmarks.
RESULTS: This is the first report exemplifying the anti-cancer effect of butein against OSCC. Our results showed that butein exhibited potent anti-proliferative, cytotoxic, anti-migratory, and anti-invasive effects in OSCC cells. It suppressed the expression of NF-κB and NF-κB-regulated gene products such as COX-2, survivin and MMP-9 which are involved in the regulation of different processes like proliferation, survival, invasion, and metastasis of OSCC cells. Conclusion Collectively, these results suggest that butein has immense potential in the management of OSCC. Nonetheless, in vivo validation is critical before moving to clinical trials.

Entities:  

Keywords:  NF-KB; Proliferation; butein; oral squamous cell carcinoma; survival

Mesh:

Substances:

Year:  2019        PMID: 31759370      PMCID: PMC7063020          DOI: 10.31557/APJCP.2019.20.11.3437

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


Introduction

Oral cancer presents one of the major health concerns of people worldwide, accounting for 2–4% of all cancer cases. It includes a group of neoplasms affecting any region of the oral cavity, pharyngeal regions, and salivary glands. Notably, in some regions, the prevalence of oral cancer is even higher, reaching around 45% in India and 10% in Pakistan of all cancers (Herrero et al., 2003; Pires et al., 2013 ; Markopoulos, 2012). On the basis of epidemiological and clinicopathological standpoints, oral cancer can be divided into three distinct classes, such as carcinomas of the oral cavity proper, carcinomas of the lip vermilion, and carcinomas arising in the oropharynx. It is more common among older and middle-aged people compared to younger adults. Further, recent reports suggest that intraoral and oropharyngeal tumors occur more commonly among men than women, with a male: female ratio of 2:1. Consumption of tobacco, alcohol, chronic use of betel quid, human papillomavirus, and oral lichen planus have been identified as major risk factors of oral cancer (Neville and Day, 2002; Ram et al., 2011). It has been estimated that more than 90% of all oral cancers are oral squamous cell carcinomas (OSCC) (Pires et al., 2013). Notably, despite the tremendous advancements made in surgery, radiotherapy, and chemotherapy, the survival rate of oral cancer has not shown any appreciable improvement; rather, it remains quite low at around 50-55%. This is primarily due to current therapeutic regimens being of minimal efficacy and being associated with diverse adverse reactions. Further, they are very expensive and hence beyond the reach of the vast majority of the world’s population. This necessitates discovering alternate regimens that are effective, devoid of extreme toxicities, and inexpensive for treating this neoplasm (Bordoloi et al., 2016; Kunnumakkara et al., 2017; Kunnumakkara et al., 2019a). Numerous epidemiological, clinical, and experimental studies suggest that natural products possess enormous therapeutic potential for the prevention and treatment of different malignancies (Deorukhkar et al., 2007; Pandey et al., 2007; Shanmugam et al., 2011a; Yang et al., 2013; Dai et al., 2015a; Hsieh et al., 2015; Roy et al., 2016; Shanmugam et al., 2016; Yarla et al., 2016; Harsha et al., 2017; Hasanpourghadi et al., 2017; Shanmugam et al., 2017; Banik et al., 2018; Jayasooriya et al., 2018; Khwairakpam et al., 2018; Kunnumakkara et al., 2019b). For instance, various plant polyphenols have been suggested to inhibit tumorigenesis and carcinogenesis of skin, liver, colon and lung cells (Lambert et al., 2005; Li F et al., 2010; Tan et al., 2010; Rajendran et al., 2011a; Rajendran et al., 2011b; Chan et al., 2012; Rajendran et al., 2012; Manu et al., 2013; Subramaniam et al., 2013; Sethi et al., 2014; Siveen et al., 2014a; Tang et al., 2014; Dai et al., 2015b; Lee et al., 2015; Amararathna et al., 2016; Dai et al., 2016; Ko et al., 2018). Butein is a one such potent polyphenol that was first isolated from Toxicodendron vernicifluum (also known as Rhus verniciflua), (Figure 1) with enormous medicinal values that have been utilized since ancient times (Chua et al., 2010; Padmavathi et al., 2015; Song et al., 2016). This plant has been used in the treatment of gastritis, atherosclerosis, and various other diseases such as inflammatory diseases, hepatic disorders, cancers, bleeding, and cough, and has also been used as a pain killer, antioxidant, and antibacterial agent (Padmavathi et al., 2015). It is present in numerous other plants as well, which include the stem-bark of cashews (Semecarpus anacardium), and herbs such as Caragana jubata and the heartwood of Dalbergia odorifera (Moon et al., 2010b). Research over the past few decades has revealed butein to be a potent, multi-targeted flavonoid. It exhibits anti-inflammatory, anti-platelet, anti-restenosis, anti-diabetic, and anti-nephritic activities, exemplifying its multi-targeting potential (Padmavathi et al., 2015). Further, it exhibits anti-tumor activity against a variety of human tumor cells, including colon carcinoma, osteosarcoma, breast carcinoma, hepatocarcinoma, and lymphoma (Jayasooriya et al., 2018). Butein was shown to alter the expression and activity of several genes, transcription factors, enzymes, and proteins involved in important cellular processes essential for tumor initiation, progression, and chemoresistance (Padmavathi et al., 2017). The major molecular target affected by butein treatment in most of the diseases investigated is the transcription factor nuclear factor κB (NF-κB) (Padmavathi et al., 2017). Over the last decade, NF-κB became a major target in drug discovery due to its key role in cancer development, cell proliferation and survival, inflammation, and immune responses (Ahn et al., 2007; Sethi et al., 2008; Sethi et al., 2009; Li and Sethi, 2010; Orlikova et al., 2012; Sethi et al., 2012; Shin et al., 2014; Li et al., 2015b; Monisha et al.,2016; Monisha et al., 2017; Ningegowda et al., 2017; Pires et al., 2018; Mohan et al., 2018; Puar et al., 2018). Hence, in this study we aimed to evaluate the effect of butein on NF-κB and its regulated gene products in OSCC cells.
Figure 1

A, Toxicodendron vernicifluum, the plant from which Butein was first isolated; B, Chemical structure of Butein

Materials and Methods

Reagents Butein was obtained from TCI, Japan. A 50 mM solution of butein was prepared in dimethyl sulfoxide (DMSO), stored as small aliquots at -20°C, and then diluted as needed in cell culture medium. Penstrep, DMEM medium, and fetal bovine serum were obtained from Gibco, USA. MTT and Propidium iodide were obtained from Sigma Aldrich and DMSO used was from Merck Life Science Pvt. Ltd. Antibodies against p65, MMP-9, COX-2, and survivin were obtained from Cell signaling technologies, USA. The live and dead assay kit was obtained from Life technologies. The Matrigel invasion assay kit was obtained from Corning, New York, USA. Cell lines Cell lines SAS and KB (human oral squamous cancer cells) were obtained from NCCS (Pune, India). The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1 % Penstrep. DPPH free radical scavenging assay 2,2-Diphenyl–1–picrylhydrazyl (DPPH∙) was used to measure the free radical scavenging activity of butein. DPPH stable free radicals are reduced to DPPH-H, leading to discoloration from purple to yellow and consequently a decrease in absorbance. The degree of discoloration indicates the scavenging potential of the antioxidant compounds (Wang and Wink, 2016). To perform this assay, 0.1 mM solution of DPPH in methanol was prepared and 100μl of this solution was added to different concentrations of butein (0, 25, 50 and 100 µM). After 30 minutes of incubation, the absorbance was measured at 517nm using a microplate reader (TECAN Infinite 200 PRO multimode reader). Curcumin at various concentrations (0, 25, 50, and 100 μM) was used as a reference compound. The lower the absorbance of the reaction mixture indicates a higher free radical scavenging activity. The capability to scavenge DPPH free radicals was calculated using the following equation: Radical Scavenging (%)=((OD of Control- OD of Sample)/OD of Control)×100, where OD is optical density (Banothu et al., 2018). The graph was plotted as the percentage of DPPH inhibition vs. concentration. Viability assay The effect of butein on the viability of OSCC cells was determined using an MTT assay. Briefly, 2,000 cells were seeded in 96 well plates and incubated for 24h at 37°C and then treated with different concentrations of butein (0, 1, 10, 25, 50, and 100 µM). The MTT assay was performed at 24, 48, and 72h. 10µl of 5mg/ml of MTT solution was added to each well and incubated for 2h. After that the culture medium was removed and 100µl of DMSO was added to all the wells and incubated at room temperature for 1h to dissolve the MTT-formazan product. Finally, absorbance of the colored solution was measured with a microplate reader (TECAN Infinite 200 PRO multimode reader) at 570 nm. The inhibition caused by butein on the growth of SAS and KB cells was determined by the percentage of viability. Colony formation assay The clonogenic potential of butein treated OSCC cells was determined using a colony formation assay. Briefly, cells were seeded in 6-well plates at low density (~1,000 cells per well) and then treated with the indicated concentrations of butein for 24h. The medium was replaced with fresh medium and the cells were cultured for 10 days. The plates were then washed with PBS and stained with crystal violet (SRL Pvt. Ltd., India). The images of each well were scanned, the individual clone types were identified, and survival fraction was determined. Propidium iodide flow cytometric assay Propidium iodide (PI), a fluorescent dye that intercalates with nucleic acids to give red fluorescence, was used to measure cell viability in flow cytometry. SAS and KB cells were seeded in 6-well plates at a concentration of 5x104 cells per well, incubated for 24h, and then treated with the indicated concentrations of butein for 24, 48, and 72h. After that, all the cells were collected, washed with PBS, and 5 µl of 1mg/ml PI was added. After incubation for 10 min, the effect of butein on the cells was analyzed using FACS (FACS Calibur™, BD Biosciences). Live cells have an intact cell membrane and hence are PI impermeable and emit less fluorescence, whereas dead cells emit a high red fluorescence due to the presence of a damaged plasma membrane. Live/Dead assay In order to measure apoptosis, we performed a Live/Dead assay, which determines intracellular esterase activity and plasma membrane integrity. Calcein-AM, a non-fluorescent polyanionic dye, is retained by live cells in which it produces intense green fluorescence through enzymatic (esterase) conversion. In addition, an ethidium homodimer enters the cells with damaged membranes and binds to nucleic acids, thereby producing a bright red fluorescence in dead cells (Lima et al., 2015). Briefly, 2x104 cells were incubated with the indicated concentrations of butein for 72h at 37°C. Cells were then stained with the Live/Dead reagent (5 µM ethidium homodimer and 5 µM calcein-AM) and incubated at 37°C for 20 min. Cells were analyzed under an inverted fluorescence microscope (Nikon, Eclipse TS100, Japan). Scratch wound healing assay This assay is performed to evaluate cell migration, where an artificial gap is created in a confluent cell monolayer and then migration of the cells from the edges over time is observed. The extent of scratch wound healing and the scratch wound healing rate denote migration characteristics of the cells. 6x105 OSCC cells were seeded in 6-well cell culture plates and cultured to a confluent monolayer. After the monolayer was formed, the medium was replaced with serum free medium and the cells were incubated for 8h. Then the medium was removed and a pipette tip (200 μl) was used to scratch a wound in the midline of the culture well, and then the cells were washed twice with PBS to remove any debris. Cells were then treated with the indicated concentration of butein. The migration of the cells was evaluated by observing the difference in the area of the scratch wounds using an inverted microscope (Nikon T1-SM, Japan). Images were taken at 0 and 24h and analyzed using Image J software. As KB cells mostly formed colonies, no monolayer was obtained and hence this assay was performed for SAS cells only. Invasion assay Invasion through the extracellular matrix is a crucial step in tumor metastasis. The invasive potential of butein-treated OSCC cells was carried out using a Boyden chamber assay. OSCC cells were serum starved for 18h before seeding to transwell migration chambers. 24-well, 8mm pore transwell inserts (Corning, USA) pre-coated with Matrigel were used. Post serum starvation, the cells were trypsinized and were seeded at a concentration of 5x104 cells in the upper chamber of the transwell insert in 500µl of serum free medium and then treated with the indicated concentrations of butein. Then 750µl of medium containing 10% FBS was added to the lower chamber as a chemo-attractant. Cells were then incubated for another 24h at 37°C. The non-migrating cells on the upper surface of the membrane were then scraped off with cotton swabs. The migrated cells at the bottom of the transwell insert were fixed in 70% ethanol and were stained with crystal violet solution. Stained cells were visualized under an inverted microscope (Nicon Eclipse TS100), the membrane was dissolved in 1% SDS solution at 37°C for 1h and absorbance was read at 595nm using a microplate reader (TECAN Infinite 200 PRO multimode reader). Western blot analysis To determine the effect of butein on p65 phosphorylation, cytoplasmic and nuclear extracts were prepared. For the detection of anti-apoptotic, invasion, and metastasis markers, whole cell extracts were prepared by subjecting butein-treated cells to lysis in lysis buffer (20mM HEPES, 2mM EDTA, 250mM NaCl, 0.1% NP40) in the presence of protease inhibitors (2µg/ml Leupeptin hemisulfate, 2µg/ml aprotinin, 1mM PMSF, 1mM DTT). Lysates were spun at 13,000 g for 10 min to remove insoluble material. Supernatants were collected and kept at -80°C. Both cytosolic or nuclear extracts and whole cell lysates were resolved by SDS-PAGE. After electrophoresis, the proteins were electro transferred to nitrocellulose membranes, blotted with the relevant antibodies, and detected using an Opti blot ECL Detection Kit (Abcam, USA). Statistical analysis All data were derived from at least three independent experiments. The blots were visualized with the chemi-doc system (BIORAD). Images were captured and analyzed using Image-Lab software. Image J software was also used for the analysis of the images. Statistical analyses were conducted using Student’s t-test, and values are presented as mean ± standard deviation (SD). A value of P < 0.05 was considered statistically significant.

Results

The study was designed to evaluate the anti-cancer effect of butein on human OSCC cells. Additionally, we attempted to explore potential mechanism(s) through which butein exerts its effect on OSCC cells. Butein exhibited radical scavenging activity A DPPH assay was conducted to assess the radical scavenging effect of butein. Curcumin (Akay Flavours and Aromatics Pvt. Ltd., India) was used as a positive control. The ability to scavenge the DPPH radicals was calculated and the results indicate that butein exhibits a strong radical scavenging effect (Figure 2A).
Figure 2

A, Anti-oxidant effect of butein evaluated using DPPH assay. The graph shows % scavenging activity of the indicated concentrations of butein and curcumin. Results are represented as Mean ± SD of three independent experiments. Cell viability of SAS cells (B) and KB cells (C) was determined with the help of MTT assay. After 24, 48 and 72 hr drug exposure with the indicated concentrations of butein, cells were incubated with MTT for 2 hr. Absorbance values were measured at 570 nm. Colony formation assay of SAS cells (D) and KB cells (E) was done to investigate the suppressive effect of butein on the clonogenic potential of human OSCC cells. Data are presented as mean ± SD of three independent experiments, *p < 0.05 vs. control

Butein reduced the viability of OSCC cells in vitro We examined whether butein could affect the viability of human OSCC cells by using an MTT assay and colony formation assay. Butein was found to effectively reduce the viability of SAS (Figure 2B) and KB (Figure 2C) cells. Overall, this activity of butein was dose-dependent as well as time-dependent. Further, a colony formation assay was performed to investigate the long-term effect of butein on the proliferation of OSCC cells. The colony-forming ability of both SAS (Figure 2D) and KB (Figure 2E) cells was reduced after exposure to butein. Additionally, the reduction was even more remarkable at higher concentrations i.e. 50 and 100 µM. Butein induced apoptosis in OSCC cells The apoptotic effect of butein was evaluated using PI FACS and live and dead assay. Both SAS and KB cells were treated with different concentrations of butein for 24, 48, and 72 hr following which apoptosis was determined by flow cytometry analysis. As shown in Figure 3, treatment of SAS (Figure 3A) and KB (Figure 3B) cells with different concentrations of butein for different time periods resulted in cell death, which was found to be dose- as well as time-dependent.
Figure 3

Butein Induces Cytotoxic Effect to the Oral Cancer Cells. (A): SAS and (B): KB cells were treated with the indicated concentrations of butein for 24, 48 and 72 h, followed by PI staining and FACS analysis for the cell death profile. Live and dead assay was performed to evaluate the apoptotic effect of the indicated concentrations of butein on OSCC cells. Quantification of the number of live (green) and dead cells (red) was done with the help of Image J software in butein treated (C) SAS cells and (D) KB cells. Results presented are mean ± SD of three independent experiments, *p < 0.05 vs. control

Further, in a live and dead assay, butein treatment showed a dose-dependent toxic effect on OSCC cells. The effect was more pronounced at concentrations beyond 25 µM. This dose-dependent reduction of viable cells is in agreement with the results of the PI FACS analysis (Figures 3C and D). Butein inhibited the migration and invasion of OSCC cells Cell migration was assessed by quantifying the percentage of wound closure in the scratch wound-healing assay. Butein treated cells exhibited lower values of migration ability with respect to those obtained by the untreated cells. In addition, butein was found to inhibit the migration of SAS cells dose-dependently (Figure 4A). We also examined the effect of butein on the invasive properties of SAS cells using a Matrigel invasion assay (Figure 4B). The results demonstrated that the invasion of cells was very low after treatment with butein compared to the untreated cells. Notably, the anti-invasive effect of butein was found to increase proportionately with the increased concentrations of butein. At 25 µM concentration of butein treatment, 50 % inhibition in the invasive capacity of SAS cells was observed.
Figure 4.

(A), Effect of butein on the migration of SAS cells in vitro. SAS cells were scratch-wounded and then treated with the indicated concentrations of butein followed by recording of wound areas at 0 and 24 hr. % wound area remaining was calculated using Image J software; (B), Anti-invasive effect of butein on SAS cells using a matrigel invasion assay where transwell inserts pre-coated with matrigel were used to measure the in vitro invasiveness. The % invaded cells were significantly reduced by butein treatment. Results are presented as mean ± SD of three independent experiments, *p < 0.05 vs. control

Butein inhibited NF-κB activation and NF-κB-regulated proteins associated with proliferation, survival, invasion, and metastasis of OSCC cells As NF-κB has been linked with both proliferation and chemoresistance in cancer cells (Li and Sethi, 2010; Kannaiyan et al., 2011; Manu et al., 2014; Siveen et al., 2014b; Li et al., 2015b; Manu et al., 2018), we further examined whether butein could inhibit constitutive activation of NF-κB in OSCC cells. Our results showed that this flavonoid inhibited the activation of NF-κB. Further, we examined whether butein downregulated the expression of the proteins involved in proliferation, survival, invasion, and metastasis in both SAS (Figure 5A) and KB (Figure 5C) cells. The results showed that this compound downregulated the expression of survivin in both cell lines (Figures 5A-D). In addition, the expression of cyclooxygenase-2; COX-2 and matrix metalloproteinase 9; MMP-9 were also suppressed by butein in SAS cells (Figures 5A and 5B). Further, in KB cells, butein downregulated the expression of COX-2; whereas in the case of MMP-9, downregulation was observed upon treating with 25 and 50 µM of butein (Figures 5C and 5D).
Figure 5

Effect of Butein on NF-κB and NF-κB Regulated Gene Products. Representative western blots showing p65, phospho p65, survivin, COX-2 and MMP-9 in (A) SAS and (C) KB cell lysates after treating with the indicated concentrations of butein. Densitometric analysis of phospho p65, survivin, COX-2 and MMP-9 in (B) SAS cells and (D) KB cells. Data are expressed as mean ± SD (n=3), * denotes P<0.05 vs. Control

A, Toxicodendron vernicifluum, the plant from which Butein was first isolated; B, Chemical structure of Butein A, Anti-oxidant effect of butein evaluated using DPPH assay. The graph shows % scavenging activity of the indicated concentrations of butein and curcumin. Results are represented as Mean ± SD of three independent experiments. Cell viability of SAS cells (B) and KB cells (C) was determined with the help of MTT assay. After 24, 48 and 72 hr drug exposure with the indicated concentrations of butein, cells were incubated with MTT for 2 hr. Absorbance values were measured at 570 nm. Colony formation assay of SAS cells (D) and KB cells (E) was done to investigate the suppressive effect of butein on the clonogenic potential of human OSCC cells. Data are presented as mean ± SD of three independent experiments, *p < 0.05 vs. control Butein Induces Cytotoxic Effect to the Oral Cancer Cells. (A): SAS and (B): KB cells were treated with the indicated concentrations of butein for 24, 48 and 72 h, followed by PI staining and FACS analysis for the cell death profile. Live and dead assay was performed to evaluate the apoptotic effect of the indicated concentrations of butein on OSCC cells. Quantification of the number of live (green) and dead cells (red) was done with the help of Image J software in butein treated (C) SAS cells and (D) KB cells. Results presented are mean ± SD of three independent experiments, *p < 0.05 vs. control (A), Effect of butein on the migration of SAS cells in vitro. SAS cells were scratch-wounded and then treated with the indicated concentrations of butein followed by recording of wound areas at 0 and 24 hr. % wound area remaining was calculated using Image J software; (B), Anti-invasive effect of butein on SAS cells using a matrigel invasion assay where transwell inserts pre-coated with matrigel were used to measure the in vitro invasiveness. The % invaded cells were significantly reduced by butein treatment. Results are presented as mean ± SD of three independent experiments, *p < 0.05 vs. control Effect of Butein on NF-κB and NF-κB Regulated Gene Products. Representative western blots showing p65, phospho p65, survivin, COX-2 and MMP-9 in (A) SAS and (C) KB cell lysates after treating with the indicated concentrations of butein. Densitometric analysis of phospho p65, survivin, COX-2 and MMP-9 in (B) SAS cells and (D) KB cells. Data are expressed as mean ± SD (n=3), * denotes P<0.05 vs. Control

Discussion

Butein is a biologically active flavonoid, which is known to have therapeutic potential against various cancers (Padmavathi et al., 2015; Jayasooriya et al., 2018). It targets different proteins such as EGFR, COX-2, STAT3, ERK, JNK, Akt, p38, caspases, Bax etc. which regulate different processes in cancer cells like survival, proliferation, invasion, metastasis, chemoresistance, radiation resistance, and cell death (Padmavathi et al., 2015). Notably, this is the first report to describe the anti-cancer potential of butein against OSCC. Our results showed this flavonoid to effectively modulate the viability, clonogenic potential, apoptosis, migration as well as invasion of OSCC cells plausibly through the involvement of NF-κB and NF-κB regulated gene products which play critical role in regulating diverse cancer hallmarks. In this study, it was observed that butein showed high antioxidant activity. In line with this result obtained, previous report has also indicated the powerful antioxidant role of butein against lipid and LDL peroxidation via free radical scavenging processes and metal ion chelation (Cheng et al., 1998). Antioxidants are known to mediate the key activities of cellular integrity maintenance and thus maintains the homeostasis of the host immune system. The genomic integrity of a cell is determined by the balance of pro-oxidants and the levels of antioxidants and an aberration in this balance can alter the normal cellular signaling cascades (Thyagarajan et al., 2018). Further, the alterations in the cellular signaling pathway can initiate the process of neocarcinogenesis (Monisha et al., 2017; Roy et al., 2017). In addition, as mentioned above, the current investigation suggested that the treatment of butein caused antiproliferative and cytotoxic effects against OSCC cells. Similarly, the preceding reports have also suggested the same activities against different cancer cells such as breast, blood, liver, cervical etc. (Yang et al., 2012; Liao et al., 2018; Tang et al., 2016; Yang et al., 2018). For instance, Yang et al., (2018) reported that butein reduced the viability of cervical cancer cells through a pro-apoptotic effect by blocking inhibitor of apoptosis (IAP) proteins and activating extrinsic as well as intrinsic pro-apoptotic cascades. Further, it inhibited the proliferation and survival of HCC ells effectively (Liao et al., 2018; Zhou et al., 2018). In addition, butein was also reported to exert its antiproliferative and pro-apoptotic effect through inhibition of NF-κB, AP-1 and Akt signaling in HTLV-1-infected T cells in both in vitro and in vivo settings clearly indicating its therapeutic potential against adult T-cell leukemia/lymphoma (Ishikawa et al., 2017). Besides, this flavonoid induced apoptosis and arrest at the G2/M phase of cell cycle through PERK/eIF-2α/CHOP pathway dependent ROS generation (Di et al., 2019). This study also showed that butein inhibited the migration and invasion of OSCC cells. In line with our findings, Lai et al., (2015) also reported that butein inhibited the migration of B16F10 melanoma cells in a concentration-dependent manner. Further it exerted a dose-dependent effect on focal adhesion kinase, Akt, and ERK phosphorylation in B16F10 cells. In addition, its treatment led to the inhibition of cell adhesion, migration and invasion of NSCLC cells (Di et al., 2019). Zhang et al., (2008) also reported this compound to inhibit the migration as well as invasion of bladder cancer cells by modulating ERK1/2 and NF-kB signaling. Further, in case of HCC as well, butein was found to inhibit the migration and invasion of SK-HEP-1 human HCC cells via ERK, JNK, p38, and uPA signaling cascades (Ma et al., 2011). Another study reported this compound to be a novel inhibitor of CXCR4 and thus found to hold immense potential in suppressing metastasis in pancreatic cancer and also in case of breast cancer, the most predominant cancer type among women across the world (Chua et al., 2010; Thakur et al., 2018). Further, a detailed analysis of the underlying mechanism of action of butein was also carried out in this study. Notably, the recent studies reported NF-κB and NF-κB regulated proteins to be the major targets of this compound (Padmavathi et al., 2015; Padmavathi et al., 2017). It was found to exhibit the effect by suppressing NF-κB in different cancer cell lines such as breast, bladder, hepatoma, lung, leukemia, pancreatic, and prostate (Pandey et al., 2007; Zhang et al., 2008; Chua et al., 2010; Moon et al., 2010a, Moon et al., 2010b; Ishikawa et al., 2017). It has been well established that NF-κB plays a pivotal role in inflammatory and immune responses and regulates the expression of a variety of important genes associated with different hallmarks of cancer (Manu et al., 2011; Shanmugam et al., 2011b; Manu et al., 2012; Li et al., 2013; Li et al., 2015a; Li et al., 2015b; Monisha et al., 2017; Ningegowda et al., 2017) . However, the effect of butein on NF-κB, as well as diverse gene products regulated by NF-κB, in human OSCC cells has not been previously elucidated. Our results showed that butein suppressed the expression of COX-2, survivin and MMP-9. COX-2 is known to be involved in the modulation of cell proliferation and apoptosis in different tumors (Zarghi et al., 2011). Further, survivin which belongs to IAP protein family is involved in inhibiting caspases as well as blocking cell death (Jaiswal et al., 2015). MMP-9 is strongly involved in the regulation of cancer cell invasion, metastasis and angiogenesis (Huang, 2018). Further, butein also suppressed the activation of NF-κB in OSCC cells. These results are in agreement with the previous reports of butein on different tumor cells. For instance, a study conducted by Pandey et al., (2007) demonstrated that the anti-tumor effect exerted by butein was mediated via inhibition of IKK, resulting in the suppression of the NF-κB pathway. Another study showed that this chalcone caused repression in the invasion of bladder cancer cells through NF-κB and ERK1/2 signaling cascades (Zhang et al., 2008). Further, butein inhibited tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated activation of NF-kB in human hepatoma cells (Moon et al., 2010b). In addition, butein inhibited the invasion and angiogenesis in prostate cancer cells through blockade of NF-κB activity (Moon et al., 2010a). In the case of breast and pancreatic cancer cells, butein downregulated chemokine receptor CXCR4 expression and acted via suppression of NF-κB (Chua et al., 2010). Taken together, this plant polyphenol, ‘butein’ has been found to exhibit profound anti-proliferative, cytotoxic, anti-migratory, and anti-invasive effects via modulation of various gene products such as COX-2, survivin, and MMP-9. As mentioned earlier, these genes play inevitably important roles in the proliferation, survival, invasion, and metastasis of cancer cells, including OSCC. This is the first report that shows the anti-cancer effect of butein along with the possible mechanisms involved. As these gene products are regulated by NF-κB, it is a clear indication that butein exerts its anti-cancer effect via modulation of the NF-κB signaling pathway. However, further in vivo studies and clinical validation are warranted to bring this safe and efficacious compound as a forefront therapeutic option for the successful management of OSCC.
  89 in total

Review 1.  Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations.

Authors:  Joshua D Lambert; Jungil Hong; Guang-Yu Yang; Jie Liao; Chung S Yang
Journal:  Am J Clin Nutr       Date:  2005-01       Impact factor: 7.045

2.  Butein inhibits the proliferation of breast cancer cells through generation of reactive oxygen species and modulation of ERK and p38 activities.

Authors:  Li-Heng Yang; Ying-Jui Ho; Jing-Feng Lin; Chi-Wei Yeh; Shao-Hsuan Kao; Li-Sung Hsu
Journal:  Mol Med Rep       Date:  2012-08-07       Impact factor: 2.952

3.  Butein inhibits the migration and invasion of SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK, JNK, p38, and uPA signaling multiple pathways.

Authors:  Chia-Yu Ma; Wei-Ting Ji; Fu-Shin Chueh; Jai-Sing Yang; Po-Yuan Chen; Chien-Chih Yu; Jing-Gung Chung
Journal:  J Agric Food Chem       Date:  2011-08-03       Impact factor: 5.279

4.  Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation.

Authors:  Dong-Oh Moon; Mun-Ock Kim; Yung Hyun Choi; Gi-Young Kim
Journal:  Mol Cancer Ther       Date:  2010-06-01       Impact factor: 6.261

5.  Oral cancer: risk factors and molecular pathogenesis.

Authors:  Hari Ram; Jayanta Sarkar; Hemant Kumar; Rituraj Konwar; M L B Bhatt; Shadab Mohammad
Journal:  J Maxillofac Oral Surg       Date:  2011-04-22

6.  DEAD-box helicase DP103 defines metastatic potential of human breast cancers.

Authors:  Eun Myoung Shin; Hui Sin Hay; Moon Hee Lee; Jen Nee Goh; Tuan Zea Tan; Yin Ping Sen; See Wee Lim; Einas M Yousef; Hooi Tin Ong; Aye Aye Thike; Xiangjun Kong; Zhengsheng Wu; Earnest Mendoz; Wei Sun; Manuel Salto-Tellez; Chwee Teck Lim; Peter E Lobie; Yoon Pin Lim; Celestial T Yap; Qi Zeng; Gautam Sethi; Martin B Lee; Patrick Tan; Boon Cher Goh; Lance D Miller; Jean Paul Thiery; Tao Zhu; Louis Gaboury; Puay Hoon Tan; Kam Man Hui; George Wai-Cheong Yip; Shigeki Miyamoto; Alan Prem Kumar; Vinay Tergaonkar
Journal:  J Clin Invest       Date:  2014-08-01       Impact factor: 14.808

Review 7.  Butein and Its Role in Chronic Diseases.

Authors:  Ziwei Song; Muthu K Shanmugam; Hanry Yu; Gautam Sethi
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 8.  Nuclear Factor Kappa B: A Potential Target to Persecute Head and Neck Cancer.

Authors:  Javadi Monisha; Nand Kishor Roy; Devivasha Bordoloi; Amit Kumar; Ramesh Golla; Jibon Kotoky; Ganesan Padmavathi; Ajaikumar B Kunnumakkara
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

9.  Phytochemical screening and evaluation of in vitro antioxidant and antimicrobial activities of the indigenous medicinal plant Albizia odoratissima.

Authors:  Venkanna Banothu; Chandrasekharnath Neelagiri; Uma Adepally; Jayalakshmi Lingam; Kesavaharshini Bommareddy
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

10.  PERK/eIF-2α/CHOP Pathway Dependent ROS Generation Mediates Butein-induced Non-small-cell Lung Cancer Apoptosis and G2/M Phase Arrest.

Authors:  Shouyin Di; Chongxi Fan; Zhiqiang Ma; Mingyang Li; Kai Guo; Donghui Han; Xiaofei Li; Deguang Mu; Xiaolong Yan
Journal:  Int J Biol Sci       Date:  2019-06-04       Impact factor: 6.580

View more
  11 in total

Review 1.  The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.

Authors:  Elina Khatoon; Mangala Hegde; Aviral Kumar; Uzini Devi Daimary; Gautam Sethi; Anupam Bishyaee; Ajaikumar B Kunnumakkara
Journal:  Arch Pharm Res       Date:  2022-08-20       Impact factor: 6.010

2.  Exploring the Cytotoxic Effects of the Extracts and Bioactive Triterpenoids from Dillenia indica against Oral Squamous Cell Carcinoma: A Scientific Interpretation and Validation of Indigenous Knowledge.

Authors:  Maniyamma Aswathy; Kishore Banik; Dey Parama; Parameswaran Sasikumar; Choudhary Harsha; Anuja Gracy Joseph; Daisy R Sherin; Manojkumar K Thanathu; Ajaikumar B Kunnumakkara; Radhakrishnan Kokkuvayil Vasu
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-09

Review 3.  From Simple Mouth Cavities to Complex Oral Mucosal Disorders-Curcuminoids as a Promising Therapeutic Approach.

Authors:  Sosmitha Girisa; Aviral Kumar; Varsha Rana; Dey Parama; Uzini Devi Daimary; Saman Warnakulasuriya; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-17

Review 4.  COVID-19, cytokines, inflammation, and spices: How are they related?

Authors:  Ajaikumar B Kunnumakkara; Varsha Rana; Dey Parama; Kishore Banik; Sosmitha Girisa; Sahu Henamayee; Krishan Kumar Thakur; Uma Dutta; Prachi Garodia; Subash C Gupta; Bharat B Aggarwal
Journal:  Life Sci       Date:  2021-02-16       Impact factor: 5.037

Review 5.  Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties.

Authors:  Sahu Henamayee; Kishore Banik; Bethsebie Lalduhsaki Sailo; Bano Shabnam; Choudhary Harsha; Satti Srilakshmi; Naidu Vgm; Seung Ho Baek; Kwang Seok Ahn; Ajaikumar B Kunnumakkara
Journal:  Molecules       Date:  2020-05-12       Impact factor: 4.411

Review 6.  Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.

Authors:  Choudhary Harsha; Kishore Banik; Hui Li Ang; Sosmitha Girisa; Rajesh Vikkurthi; Dey Parama; Varsha Rana; Bano Shabnam; Elina Khatoon; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

Review 7.  Integrating Ethnobotany, Phytochemistry, and Pharmacology of Cotinus coggygria and Toxicodendron vernicifluum: What Predictions can be Made for the European Smoketree?

Authors:  Diana Simona Antal; Florina Ardelean; Robert Jijie; Iulia Pinzaru; Codruta Soica; Cristina Dehelean
Journal:  Front Pharmacol       Date:  2021-04-19       Impact factor: 5.810

8.  Novel Butein Derivatives Repress DDX3 Expression by Inhibiting PI3K/AKT Signaling Pathway in MCF-7 and MDA-MB-231 Cell Lines.

Authors:  Shailima Rampogu; Seong Min Kim; Baji Shaik; Gihwan Lee; Ju Hyun Kim; Gon Sup Kim; Keun Woo Lee; Myeong Ok Kim
Journal:  Front Oncol       Date:  2021-08-18       Impact factor: 6.244

Review 9.  Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer.

Authors:  Sosmitha Girisa; Dey Parama; Choudhary Harsha; Kishore Banik; Ajaikumar B Kunnumakkara
Journal:  Explor Target Antitumor Ther       Date:  2020-10-30

Review 10.  Molecular Mechanisms of Antiproliferative Effects of Natural Chalcones.

Authors:  Radka Michalkova; Ladislav Mirossay; Maria Gazdova; Martin Kello; Jan Mojzis
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.